EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Safety and efficacy of long‐term use of a buprenorphine transdermal patch system in patients with osteoarthritis and low back pain refractory to non‐opioid analgesics: Post‐marketing surveillance of 3000 cases

Takahiro Ushida, Rumiko Kanzaki, Keishi Katayama iD, Akito Ishikawa

Pain Practice · 2025

DOI: 10.1111/papr.13430 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pain Practice, 2025. Verfasst von Takahiro Ushida und 3 weiteren Autor:innen. Beteiligte Einrichtung: Aichi Medical University, Nagakute-shi, Aichi, Japan. Hauptthemen laut MEDLINE: Buprenorphine, Transdermal Patch, Product Surveillance, Postmarketing, Analgesics, Opioid. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mundipharma Japanese subsidiary of Mundipharma research limited.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective s A post‐marketing surveillance was conducted to evaluate the safety and efficacy of the buprenorphine transdermal patch under actual clinical practice.

Results

Of the 3017 patients included in the safety analysis, adverse drug reactions (ADRs) were observed in 1524 (50.5%), the most common being nausea, skin symptoms at the site of application, constipation, and vomiting. The incidences of respiratory depression and withdrawal symptoms were low, and no drug dependence was observed. Among the 2573 patients included in the efficacy analysis, the efficacy (≥2‐point improvement in the numerical rating scale) rate was 74.4%, which was significantly higher in older adults (≥65 y.o) than in younger adults. Discontinuation was mostly caused by ADRs during the early initiation phase.

Conclusion

This study demonstrated the safety and efficacy of long‐term administration of buprenorphine transdermal patches, suggesting that pain control is possible over the long term if attention is paid to ADRs in the early stages of administration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BuprenorphineTransdermal PatchProduct Surveillance, PostmarketingAnalgesics, OpioidLow Back PainOsteoarthritisHumansFemaleMaleAgedMiddle AgedAdultTreatment OutcomeAged, 80 and overAnalgesics, Non-NarcoticAdministration, Cutaneous

Stichwörter der Autor:innen

buprenorphine transdermal patch systemchronic painpost‐marketing surveillance

Substanzen

BuprenorphineAnalgesics, OpioidAnalgesics, Non-Narcotic

Autor:innen und Institutionen

  • Aichi Medical University, Nagakute-shi, Aichi, Japan.
  • Scientific Affairs Division, Mundipharma K.K., Minato-ku, Tokyo, Japan.

ORCID-Profile: Keishi Katayama

Förderung

  • Mundipharma Japanese subsidiary of Mundipharma research limited

Zitieren

APA

Ushida, T., Kanzaki, R., Katayama, K., & Ishikawa, A. (2025). Safety and efficacy of long‐term use of a buprenorphine transdermal patch system in patients with osteoarthritis and low back pain refractory to non‐opioid analgesics: Post‐marketing surveillance of 3000 cases. Pain Practice. https://doi.org/10.1111/papr.13430

Vancouver

Ushida T, Kanzaki R, Katayama K, Ishikawa A. Safety and efficacy of long‐term use of a buprenorphine transdermal patch system in patients with osteoarthritis and low back pain refractory to non‐opioid analgesics: Post‐marketing surveillance of 3000 cases. Pain Practice. 2025. doi:10.1111/papr.13430

BibTeX
@article{Ushida2025,
  author = {Ushida, Takahiro and Kanzaki, Rumiko and Katayama, Keishi and Ishikawa, Akito},
  title = {Safety and efficacy of long‐term use of a buprenorphine transdermal patch system in patients with osteoarthritis and low back pain refractory to non‐opioid analgesics: Post‐marketing surveillance of 3000 cases},
  journal = {Pain Practice},
  year = {2025},
  doi = {10.1111/papr.13430}
}
Kostenlos starten →